

Randomised double-blind placebo controlled trial of effect of Ginkgo biloba on cognitive function in mild-moderate dementia

Submission date 02/08/2002	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
Registration date 02/08/2002	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 11/07/2007	Condition category Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr James Warner

Contact details
Senior Lecturer
Imperial College School of Medicine
St Charles Hospital
Exmoor Street
London
United Kingdom
W10 6DZ
+44 (0)20 8962 4101
j.warner@ic.ac.uk

Additional identifiers

Protocol serial number
QRD/2001/01/07

Study information

Scientific Title

Acronym

DIGGER

Study objectives

Null Hypothesis: high purity ginkgo biloba extract does not improve cognition quality of life or carer burden in individuals with mild-moderate dementia. NB: this study will also assess the magnitude of the Hawthorne effect in dementia trials.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from Multi-centre Research Ethics Committee (ref: MREC/02/6/35).

Study design

Randomised double-blind placebo controlled parallel group study

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Dementia

Interventions

1. The active intervention will be concentrated, standardised Ginkgo biloba extract (25% active Ginkgo-flavoneglycosides), prepared according to accepted guidelines in a 60 mg tablet (EGB-761, Schwabe)
2. The placebo will be 60 mg of inert lactose with 2 mg quinine sulphate

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Ginkgo extract

Primary outcome(s)

Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog) at six months.

Key secondary outcome(s))

All at six months:

1. Participant: Quality of Life scale in Alheimers disease (QoL-AD), Neuropsychiatric Inventory

questionnaire (NPI), Geriatric Evaluation by Relative's Rating Instrument (GERRI), adverse events
2. Carer: European Quality of life questionnaire (EQ-5D), Zarit caregiver Burden Interview (ZBI)

Completion date

31/12/2005

Eligibility

Key inclusion criteria

1. Aged 55 years and over
2. Clinician's diagnosis of dementia
3. Presence of a carer
4. Consent of patient and carer
5. Sufficient command of English to complete questionnaires
6. Mini Mental State Examination (MMSE-23) score of 15 - 24

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Sex

All

Key exclusion criteria

1. Commencement of acetylcholinesterase therapy within two months of recruitment
2. Current anticoagulant therapy
3. Abnormal clotting profile

Date of first enrolment

01/04/2003

Date of final enrolment

31/12/2005

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Senior Lecturer
London
United Kingdom
W10 6DZ

Sponsor information

Organisation
Alzheimer's Society (UK)

ROR
<https://ror.org/0472gwq90>

Funder(s)

Funder type
Charity

Funder Name
Alzheimer's Society (UK)

Alternative Name(s)
alzheimerssoc

Funding Body Type
Private sector organisation

Funding Body Subtype
Associations and societies (private and public)

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	03/07/2007		Yes	No